BioCryst Pharmaceuticals Inc (BCRX): Total Liabilities
$633.31M
As of 2025-12-31
$1.01B
As of 2026-06-30
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $633.31M | -34.5% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $966.35M | -0.6% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $972.49M | n/a | 2025-02-25, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $633.31M | -34.5% |
| Repligen Corp (RGEN) | 2025-12-31 | $843.57M | -1.6% |
| Novavax Inc (NVAX) | 2025-12-31 | $1.30B | -40.3% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $2.48B | +45.7% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $146.92M | +5.2% |
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | $218.73M | +43.5% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $686.24M | +5.8% |
| Moderna, Inc. (MRNA) | 2025-12-31 | $3.69B | +13.8% |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $114.23M | +4.4% |
Compare BCRX, RGEN, NVAX, HALO side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗